Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 778 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07413549RecruitingPhase 1/Phase 2
Stem cell injection for hepatitis B cirrhosis
This trial tests an injection of stem cells from donated umbilical cords to see if it can help people with advanced liver scarring from hepatitis B. You may be able to join if standard treatments haven’t helped enough and you aren’t able to get a liver transplant.
WuhanAges 18–75 - NCT05829629RecruitingPhase 1
Test of an HPV vaccine-like treatment for HPV16 in women
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
BratislavaAges 18–49 - NCT07402512RecruitingPhase 3
Study of deuremidevir for RSV in infants and young children
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Xiamen, FujianAges 1 month–3 years - NCT07390955RecruitingPhase 1
Safety study of three anti-HIV antibodies in healthy adults
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
Birmingham, AlabamaAges 18–55 - NCT07390474RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
Atlanta, GeorgiaAges 18–55 - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT05989958RecruitingPhase 1/Phase 2
HepaCure for acute-on-chronic liver failure
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07364474Recruiting
Immune response to liver perfusion therapy for eye melanoma
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Boston, MassachusettsAges 18 years+ - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT06740318Recruiting
Reversing liver damage in alcohol-related hepatitis
This trial studies whether people with alcohol-related hepatitis can see their liver function improve. It looks at patients whose diagnosis is supported by blood tests and imaging, and excludes those with liver cancer.
HvidovreAges 18 years+ - NCT07343960RecruitingPhase 1
Study of Capivasertib in people with moderate liver impairment
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
Rialto, CaliforniaAges 18–80 - NCT07349654Recruiting
New stent method to reduce brain fog after TIPS procedure
This trial tests a modified stent placement technique during TIPS (a procedure to lower blood pressure in the liver) to see if it helps prevent confusion and memory problems that can happen afterward.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06857773RecruitingPhase 3
Combined pump therapy and chemo for liver-only colorectal cancer
This trial tests a treatment approach where you receive chemotherapy directly into your liver through a surgically placed pump, combined with standard systemic chemotherapy (given through a vein). The goal is to shrink liver tumors enough so they can be removed later with surgery. It is for people whose colorectal cancer has spread only to the liver and has not been treated before.
AmsterdamAges 18 years+ - NCT06263959RecruitingPhase 2
Testing a new hepatitis B pill (GST-HG131) for chronic HBV
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
BeijingAges 35–65 - NCT07335406Recruiting
H. pylori infection registry study in Shandong
This study is creating a registry of people with Helicobacter pylori (H. pylori) infection in Shandong Province who choose to have treatment. It will gather information to improve how H. pylori infections are managed.
Jinan, ShandongAges 18–80 - NCT07336797RecruitingPhase 2
Empagliflozin for weight and metabolism in HIV
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
CairoAges 18–65 - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07328711RecruitingEarly Phase 1
Immunotherapy for chronic hepatitis B after HBsAg loss
This trial tests an immunomodulatory therapy for people with chronic hepatitis B who have already cleared the surface antigen (HBsAg) with a specific treatment. It aims to understand why some people achieve a cure and how to improve outcomes.
Beijing, Beijing MunicipalityAges 18–60 - NCT06179498Recruiting
Partner navigation for hepatitis C treatment in young people who inject drugs
This trial offers a partner navigation program to help young people who inject drugs and their main injecting partner work together to get treatment for hepatitis C (a liver infection).
San Francisco, CaliforniaAges 18 years+ - NCT07308886RecruitingPhase 2
CYT107 for Kaposi sarcoma in HIV patients with low CD4
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
Bethesda, MarylandAges 18–120 - NCT07314905RecruitingPhase 3
Treatments for respiratory infections in community settings
This study is testing different treatments for people with respiratory infections like the flu who are not in the hospital. You may be able to join if you have a positive test, have symptoms like cough or fever, and start within a few days of feeling sick.
Toronto, OntarioAges 18 years+ - NCT07307586RecruitingPhase 3
Azvudine for new hepatitis B patients
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Zhengzhou, HenanAges 18–65 - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT06881238Recruiting
How hepatitis B affects inflammatory bowel disease
This study looks at how hepatitis B virus affects people with inflammatory bowel disease (IBD). It may help doctors better understand the link between the two conditions.
Tanta, GharbyeaAges 18 years+
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 778 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.